Mr. Parrish will further elaborate on IRB interpretation of protocol and consent form language considerations.
Seattle, WA (PRWEB) November 26, 2012
Quorum Review Attorney, Mitchell Parrish, JD, CIP, is co-presenting at the 2012 PRIM&R Advancing Ethical Research Conference: Guided by Principles in an Era of Change. The conference takes place in San Diego, CA, December 4-6, 2012.
Mr. Parrish is part of the annual conference’s Didactic Sessions and Workshops, Tuesday, December 4 from 10:30am to 11:45am. The topic is “Ethical Issues Involving Third Parties and Secondary Subjects in Research.” Mr. Parrish joins co-panelists Sara Goldkind, MD, Senior Bioethicist in the Office of Good Clinical Practices at Food and Drug Administration (FDA), and Robert Levine, MD, Professor of Medicine and Lecturer of Pharmacology at Yale University.
The panelists’ presentation shares how to identify when pregnant partners, caregivers, and other third parties are research subjects under DHHS and FDA regulations and guidelines. Mr. Parrish will further elaborate on IRB interpretation of protocol and consent form language considerations. The session also covers confidentiality, Health Insurance Portability and Accountability Act (HIPAA), and informed consent considerations for third parties.
Mitchell Parrish joined Quorum Review in January 2010 as an Attorney in Quorum’s Regulatory Department. Mr. Parrish earned his Juris Doctor from the University of Oregon School of Law, and is a member of the Washington State Bar, including the Health and Corporate Law sections. Additionally, Mr. Parrish is a member of the American Bar Association and is a Certified Institutional Review Board Professional (CIP). Prior to joining Quorum Review, Mr. Parish worked as Regulatory Counsel for Western IRB and as a Regulatory Advisor to the National Cancer Institute’s Central IRB.
Held in San Diego, CA, December 4-6, 2012, the annual Advancing Ethical Research Conference brings together over 3,000 industry professionals from hospitals, universities, government, and other research institutions in an educational, three-day networking opportunity.
For more information about Quorum Review’s attendance at the 2012 PRIM&R Advancing Ethical Research Conference, visit http://www.QuorumReview.com.
About Quorum Review
Quorum Review is an independent ethics review board fully accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP), and has been providing ethics review of drug and device trials since 1992. Quorum oversees research in accordance with U.S. and Canadian human research subject protection regulations and guidelines set forth by the International Committee on Harmonisation (ICH), and principles of the Belmont Report.
Quorum’s best-in-class service and support includes 14 Board meetings each week plus expedited review, 24 hour site review turnaround, 36 hour amendment review turnaround, a secure web portal, and SmartForms for online submissions. Quorum’s full service offerings include full study review in the US and Canada, a specialized Phase I team, and unique processes for post-approval and registry studies.